Abstract
The traditional linear model of the RAS has now been replaced by a dynamic system than includes a number of new components. Among them the angiotensin converting enzyme type 2 has recently become recognized as an important homeostatic factor and counterbalance to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function. However, ACE2 also has a number of important independent actions as evidence by its differential distribution in both development and in adult tissues. Studies from knockout mice suggest that ACE2 is involved in both cardiac and renal development. ACE2 is also involved in a number of disease processes, most notably ACE2 has been reported recently to be the functional receptor for the severe acute respiratory syndrome (SARS) coronavirus. A reduction in ACE2 in diabetes may also contribute to endorgan damage. ACE2 may also have important functional consequences in heart failure and pre-eclampsia. In this context, selective inhibitors of ACE2 will provide important tools for exploring the physiology and pathology of the enzyme in both heath and disease states.
Keywords: ace2, renin-angiotensin system, angiotensin II, angiotensin, hypertension, diabetes, renal impairment, sars
Current Enzyme Inhibition
Title: ACE2; an ACE up the Sleeve?
Volume: 1 Issue: 1
Author(s): M. C. Thomas and C. Tikellis
Affiliation:
Keywords: ace2, renin-angiotensin system, angiotensin II, angiotensin, hypertension, diabetes, renal impairment, sars
Abstract: The traditional linear model of the RAS has now been replaced by a dynamic system than includes a number of new components. Among them the angiotensin converting enzyme type 2 has recently become recognized as an important homeostatic factor and counterbalance to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function. However, ACE2 also has a number of important independent actions as evidence by its differential distribution in both development and in adult tissues. Studies from knockout mice suggest that ACE2 is involved in both cardiac and renal development. ACE2 is also involved in a number of disease processes, most notably ACE2 has been reported recently to be the functional receptor for the severe acute respiratory syndrome (SARS) coronavirus. A reduction in ACE2 in diabetes may also contribute to endorgan damage. ACE2 may also have important functional consequences in heart failure and pre-eclampsia. In this context, selective inhibitors of ACE2 will provide important tools for exploring the physiology and pathology of the enzyme in both heath and disease states.
Export Options
About this article
Cite this article as:
Thomas C. M. and Tikellis C., ACE2; an ACE up the Sleeve?, Current Enzyme Inhibition 2005; 1 (1) . https://dx.doi.org/10.2174/1573408052952739
DOI https://dx.doi.org/10.2174/1573408052952739 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arterial Stiffness:A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Hypertension Reviews 3D QSAR Studies on Substituted Benzimidazole Derivatives as Angiotensin II-AT<sub>1</sub> Receptor Antagonist
Current Computer-Aided Drug Design Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Current Drug Targets Strategies and Techniques for Multi-Component Drug Design from Medicinal Herbs and Traditional Chinese Medicine
Current Topics in Medicinal Chemistry Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: New Insight in Selection of Rhythm or Rate Control Therapy and Impact of Mean Platelet Volume
Current Pharmaceutical Design Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Synthesis and Biological Evaluation of Curcumin-Nitroxide-Based Molecular Hybrids as Antioxidant and Anti-Proliferative Agents
Medicinal Chemistry Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Non-Systemic Drugs: A Critical Review
Current Pharmaceutical Design